LABU vs XBIX: Leverage, Returns & Decay

Over three months to Nov 13, 2026, against its daily multiple, compounded, LABU finished 2.0 points short and XBIX 2.6 points short.

Return gap
+8.4 pts3 months to Nov 13, 2026: XBIX ahead, total return
Fee gap
0.51 ptsA year: LABU 0.96%, XBIX 0.45%, per filings dated Mar 3, 2026 and Jun 11, 2026
Overlap
–No book read for both funds
Net flow
–Needs daily flows for both funds
The answerOne drawing that carries it.

Compare two other funds

The evidenceWhy, in charts and cards.
LABU and XBIX · 3 months

Growth of 100

LABU −22.3%XBIX −13.9%
Growth of 100 in LABU and XBIX over 3 months, Aug 14, 2026 to Nov 13, 2026, with distributions reinvested. LABU ends at 77.7 (−22.3%), XBIX at 86.1 (−13.9%).

LABU −22.3%, XBIX −13.9%: XBIX +8.4 pts ahead, 3 months, Aug 14, 2026 to Nov 13, 2026.

Share

Use this comparison

Alert

LABU flows, by email on Sundays.

One-click unsubscribe. See Privacy.

Hypothetical · drag to set

Fees over time

Hypothetical. $10,000 in LABU for 10 years at 0.96% a year costs about $1,557 in fees and lost growth; XBIX at 0.45% would cost $746. Assumes 6% a year before fees, a sample rate, not a forecast.

How each fund moved

LABU · 3 months to Nov 13, 20269.1 pts short of its stated multiple
9.1 pts short of its stated multipleLABU returned −22.3% while 3 times XBI's move would have been −13.2%. Data from Aug 14, 2026 to Nov 13, 2026.XBI −4.4% ×3 implies−13.2%LABU returned−22.3%9.1 pts short of its stated multipleLABU returned −22.3% while 3 times XBI's move would have been −13.2%. Data from Aug 14, 2026 to Nov 13, 2026.XBI −4.4% ×3 implies−13.2%LABU returned−22.3%

LABU returned −22.3% while 3 times XBI's move would have been −13.2%. Data from Aug 14, 2026 to Nov 13, 2026.

Data from Aug 14, 2026 to Nov 13, 2026.
XBIX · 3 months to Nov 13, 20265.1 pts short of its stated multiple
5.1 pts short of its stated multipleXBIX returned −13.9% while 2 times XBI's move would have been −8.8%. Data from Aug 14, 2026 to Nov 13, 2026.XBI −4.4% ×2 implies−8.8%XBIX returned−13.9%5.1 pts short of its stated multipleXBIX returned −13.9% while 2 times XBI's move would have been −8.8%. Data from Aug 14, 2026 to Nov 13, 2026.XBI −4.4% ×2 implies−8.8%XBIX returned−13.9%

XBIX returned −13.9% while 2 times XBI's move would have been −8.8%. Data from Aug 14, 2026 to Nov 13, 2026.

XBIX returned −13.9% while 2 times XBI's move would have been −8.8%. Data from Aug 14, 2026 to Nov 13, 2026.

IQ Leverage Score

How closely it delivered its daily multiple over 3 months, ranked against 31 leveraged ETFs at 3x, over three months and 498 leveraged ETFs at 2x, over three months. 100 is best.

LABU scores higher · Did it keep up with its own daily multiple, compounded day by day, over three months?

LABU among the 31 leveraged ETFs at 3x, over three months

1.6, the lowest in this set98.4, the highest

XBIX among the 498 leveraged ETFs at 2x, over three months

0.1, the lowest in this set99.9, the highest

A percentile among the 31 leveraged ETFs at 3x, over three months. XBIX is a percentile among the 498 leveraged ETFs at 2x, over three months, a different set, so the two marks are not on one scale. Three months only, against the fund's own daily multiple; a different quarter can rank it very differently.

Key numbers

LABU returned, 3 months
−22.3%
XBIX returned, 3 months
−13.9%
LABU from its stated multiple: compounding −7.1 pts, gap to the daily multiple −2.0 pts
−9.1 pts
XBIX from its stated multiple: compounding −2.5 pts, gap to the daily multiple −2.6 pts
−5.1 pts

XBIX costs 0.51 points a year less.

Pair scorecard

Open the table

Points (pts) are percentage points.

Total return, 1 year+70.3%not published
What its daily multiple gave, 3 months−20.3%−11.3%
What it tracksS&P BiotechU.S. Biotech
Expense ratio0.96%0.45%
Net assets, as of Nov 12, 2026$540m$317,675
Holdings in commonnot published

The numbers behind it

Net assets: $540m on Nov 12, 2026 for Direxion Daily S&P Biotech Bull 3X ETF, and $314,629 on Nov 13, 2026 for Corgi U.S. Biotech 2x Daily ETF.

Side by side

Open the table
FundDirexion Daily S&P Biotech Bull 3X ETF · Aims to return three times the daily move of biotech (XBI)Corgi U.S. Biotech 2x Daily ETF · Aims to return twice the daily move of biotech (XBI)
IssuerDirexionCorgi
Sets out to return+3x+2x
Underlying assetXBIXBI
Segmentsectorsector
Fund returned, 3 months−22.3%−13.9%
Underlying returned, over that window−4.4%−4.4%
What the stated multiple implies, over that window−13.2%−8.8%
Difference from stated, over that window−9.1 pts−5.1 pts
Fund returned, 1 year+70.3%+22.0% (since launch, Jun 3, 2026)
Difference from stated, over that window−35.0 pts−10.2 pts (since launch, Jun 3, 2026)
Underlying volatility35%35%
Expense ratio0.96%0.45%
First tradedMay 28, 2015Jun 3, 2026
Net assets, LABU as of Nov 12, 2026 and XBIX as of Nov 13, 2026$540m$314,629

As of Nov 13, 2026. Source: ETFIQ.

The dataFull tables, method and files, one click away.

Window by window

Open the full table
1 month+2.3%+2.8%+7.8%+5.2%−5.5 pts−2.4 pts
3 months−22.3%−13.9%−13.2%−8.8%−9.1 pts−5.1 pts
6 months+24.5%–+45.9%–−21.4 pts–
1 year+70.3%–+105.3%–−35.0 pts–
3 years+238.0%–not meaningful–not meaningful–
Since launch (Not the same days: LABU May 2015 · XBIX Jun 2026)−93.0%+22.0%+285.0%+32.2%−378.0 pts−10.2 pts

– means no data for this window.

About LABU

Over the three months to Nov 13, 2026, LABU lost 22.3%, against −20.3% for three times XBI's daily moves. Read the multiple against the whole window instead and 3 times XBI's −4.4% implies −13.2%, which makes LABU look 9.1 points short. That is not the fund's objective, which is daily. Of that 9.1, daily compounding is −7.1 points, which any 3 times fund would show over the same path, and the fund itself is −2.0 points against 3 times each day's move, compounded. LABU aims to return +3 times XBI's move each day, then resets. Over one day it does that. Over longer periods the daily results compound, so the total is not +3 times the period's move: it is lower after a fall and recovery, and can be higher in a steady run. XBI moved at 35% annualized over that window. The more it moves, the further the two numbers separate.

About XBIX

Over the three months to Nov 13, 2026, XBIX lost 13.9%, against −11.3% for twice XBI's daily moves. Read the multiple against the whole window instead and 2 times XBI's −4.4% implies −8.8%, which makes XBIX look 5.1 points short. Of that 5.1, daily compounding is −2.5 points, which any 2 times fund would show over the same path, and the fund itself is −2.6 points against 2 times each day's move, compounded. XBIX aims to return +2 times XBI's move each day, then resets. Over longer periods the daily results compound, so the total is not +2 times the period's move: it is lower after a fall and recovery, and can be higher in a steady run.

Questions people ask

Which came closer to its daily multiple, LABU or XBIX?

Over the window to Nov 13, 2026, LABU finished 9.1 points from what its multiple implies and XBIX finished 5.1 points from its own, so XBIX came closer. Neither number predicts the next window: it depends on how much the underlying moves about.

Are LABU and XBIX levered on the same thing?

Yes. Both are levered on biotech, LABU at +3 times and XBIX at +2 times the daily move.

Which one decays faster, LABU or XBIX?

Decay follows how much the underlying moves about. Over this window LABU’s moved at 35% annualized and XBIX’s at 35%, so LABU has the rougher ride and, at the same multiple, loses more to compounding.

Can I hold LABU or XBIX for a year?

Both reset every day, so the multiple in the name applies to a single day, and daily results compound. Over a year the total is not the multiple times the year’s move; after a fall and recovery it is lower.

Which is cheaper, LABU or XBIX?

LABU charges 0.96% a year and XBIX charges 0.45%, so XBIX is cheaper. Fees come from each fund's prospectus.

Other comparisons

Sources

More

Links are sources, not endorsements. A comparison is not a recommendation.

Copy and cite

Cite this pageCitation, APA and Markdown

ETFIQ, LABU against XBIX, data as of Nov 13, 2026. https://etfiq.com/compare/leverage/labu-vs-xbix

Open data

Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.